%0 Journal Article
%A Shah, Jatin
%A Shacham, Sharon
%A Kauffman, Michael
%A Daniele, Patrick
%A Tomaras, Dimitrios
%A Tremblay, Gabriel
%A Casasnovas, Rene-Olivier
%A Maerevoet, Marie
%A Zijlstra, Josee
%A Follows, George
%A P Vermaat, Joost S
%A Kalakonda, Nagesh
%A Goy, Andre Henri
%A Choquet, Sylvain
%A Den Neste, Eric Van
%A Hill, Brian T
%A Thieblemont, Catherine
%A Cavallo, Federica
%A la Cruz, Fátima de
%A Kuruvilla, John
%A Hamad, Nada
%A Bouabdallah, Reda
%A Jäger, Ulrich
%A Caimi, Paolo
%A Gurion, Ronit
%A Warzocha, Krzysztof
%A Bakhshi, Sameer
%A Sancho, Juan Manuel
%A Schuster, Michael
%A Egyed, Miklós
%A Offner, Fritz
%A Vasilakopoulos, Theodoros P
%A Samal, Priyanka
%A Nagy, Agnes
%A Ku, Matthew
%A Canales Albendea, Miguel Ángel
%T Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
%D 2021
%U http://hdl.handle.net/10668/17083
%X Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p 
%K EQ-5D-5L
%K FACT-Lym
%K diffuse large B-cell lymphoma
%K disutility of adverse events
%K health state utility
%K health utility
%K health-related quality of life
%K patient-reported outcomes
%K selinexor
%~